Index

A

AKT
γ chain family cytokine signaling, 9
T-cell development role, 279

AMPs. See Antimicrobial peptides

Antimicrobial peptides (AMPs), 456

Arid5a, 94

Atopic dermatitis
interleukin-17 studies, 130
interleukin-22 therapeutic targeting, 169

B

B cell
γ chain family cytokine function, 16–18
interferon-γ in activation, 226–227
tumor necrosis factor in development and function, 105

BCL11B, 280–281

β Common family cytokines. See also specific cytokines
cancer studies, 46
functions, 43–44
nervous system function, 46–47
overview, 40–43
receptors
activation, 48–49, 51
assembly, 48
assembly, 48–51
interactions with other receptors, 47–48
proximal activation of signaling, 52–53
sepsis and inflammation studies, 44–45
therapy, 41–42, 53–56
BLIMP1, 15
Briakinumab, 151

C

Candida albicans, interleukin-17 studies, 129

CAPS. See Cryopyrin-associated periodic syndromes

Castleman disease, tocilizumab therapy, 89

CD. See Crohn's disease

Ciliary neurotrophic factor (CNTF)
overview, 72–73
mutations and disease, 76
trans-signaling, 75

CISH, 317–318

CNTF. See Ciliary neurotrophic factor

Crohn's disease (CD)
γ chain family cytokine studies, 20
interleukin-10 studies, 159, 161–162
interleukin-22 therapy, 170–172

CRS. See Cytokine release syndrome

Cryopyrin-associated periodic syndromes (CAPS),
262–263

CTCL. See Cutaneous T-cell lymphoma

Cutaneous T-cell lymphoma (CTCL), interleukin-15 role, 448

Cytokine release syndrome (CRS), interleukin-6 therapeutic targeting, 93, 94

Cytokine studies
agonist development, 458–459
alarmins, 456–457
antagonist development, 459–460
assay development, 457
definition, 455–456
historical perspective, 456
mimics, 457
mutation studies, 458
signaling studies, 457–458

D

Daclizumab, 21

DC. See Dendritic cell

Dendritic cell (DC)
classical dendritic cells
cDC1 development and function, 397–398
cDC2 development and function, 398–399
GM-DCs, 403–404
human cell features, 401–402
identification
mouse bone marrow, 396–397
surface markers for in vivo identification, 403
maturation, 404–406
Mo-DCs, 403

γ chain family cytokine function, 19
interferon-γ in activation, 226
long noncoding RNA regulation of differentiation, 297–298
plasmacytoid dendritic cells
development and function, 399–400
human cell features, 402
subsets, 395

Diabetes type 1, γ chain family cytokine studies, 20–21

Diabetic foot ulcer (DFU), interleukin-20 family member therapy, 174–175

E

Ectodysplasin, 104

EPO. See Erythropoietin

Erythropoietin (EPO), receptor, 47–48

© 2018 by Cold Spring Harbor Laboratory Press. All rights reserved.
Index

F
Familial Mediterranean fever (FMF), 263–264
FGK 4.5, 444
FMF. See Familial Mediterranean fever
Follicular lymphoma, interferon-α therapy, 437
FOXP3, 11, 332

G
γ Chain family cytokines. See also specific cytokines
autoimmune disease role, 19–22
B-cell function, 16–18
gene expression mediation, 9–10
natural killer cell function, 18–19
overview, 1–5
receptors, 5–7
signaling, 7–9
structure, 2
T-cell function
CD8⁺ T-cell development and differentiation, 16
development, 10–11
helper T-cell differentiation, 12–16
Tregs, 11–12
therapy, 22–25
GATA3
helper T cells
differentiation role, 330–332
expression by noncanonical Th cell subtypes,
332–333
T-cell development role, 273–274, 277–280
GCA. See Giant cell arteritis
Giant cell arteritis (GCA), toclizumab therapy, 92
GM-CSF. See Granulocyte macrophage colony-stimulating factor
Graft-versus-host disease (GVHD), interleukin-22
protective effects, 173–174
Granulocyte macrophage colony-stimulating factor (GM-CSF)
cancer immunotherapy, 439–440
cancer studies, 46
functional overview, 43–44
nervous system function, 46–47
receptor, 48–53
sepsis and inflammation role, 45
therapeutic targeting, 53–55
GVHD. See Graft-versus-host disease

H
HEB, T-cell development role, 280–281
Hepatitis
interferon-γ therapy, 176
interleukin-22 protective effects, 173
HHV8. See Human herpes virus 8
Human herpes virus 8 (HHV8), interleukin-6, 73

I
ID2, 400
IFN. See Interferon
IFN-α. See Interferon-α
IFN-γ. See Interferon-γ
IL-1. See Interleukin-1
IL-2. See Interleukin-2
IL-3. See Interleukin-3
IL-4. See Interleukin-4
IL-5. See Interleukin-5
IL-6. See Interleukin-6
IL-7. See Interleukin-7
IL-9. See Interleukin-9
IL-10. See Interleukin-10
IL-11. See Interleukin-11
IL-12. See Interleukin-12
IL-13. See Interleukin-13
IL-15. See Interleukin-15
IL-17. See Interleukin-17
IL-19. See Interleukin-19
IL-20. See Interleukin-20
IL-21. See Interleukin-21
IL-22. See Interleukin-22
IL-23. See Interleukin-23
IL-24. See Interleukin-24
IL-26. See Interleukin-26
IL-28. See Interleukin-28
IL-29. See Interleukin-29
IL-33. See Interleukin-33
IL-37. See Interleukin-37
ILC. See Innate lymphoid cell
Inflammation
autoinflammatory disease. See Interleukin-1
β common family cytokine studies, 44–45
granulocyte macrophage colony-stimulating factor role, 45
interleukin-17 studies
IL-17B, 131
IL-17C, 131–132
IL-17D, 132
IL-17E, 132
tumor microenvironment, 414
tumor necrosis factor role, 103
Innate lymphoid cell (ILC)
cytokine regulation
group 1 cells, 382–383
group 2 cells, 383–385
group 3 cells, 385–387
interferon, 382–383
interleukin-1, 387
interleukin-2, 381–382, 386
interleukin-4, 384–385
interleukin-5, 384, 389
interleukin-7, 381–382, 386
interleukin-9, 384–385
interleukin-12, 388
interleukin-13, 384
interleukin-15, 381–382
interleukin-17, 386–387
interleukin-22, 386–387
overview, 380–382

© 2018 by Cold Spring Harbor Laboratory Press. All rights reserved.
plasticity modulation, 387–388
  tumor immunity, 388–389
  functional overview, 379–380
  subsets, 380
  Th cell relationship, 335–336
  Innate repair receptor (IRR), 47–48
  Interferon (IFN)
    cancer studies, 197
    classes, 203–204, 206
    classification, 436
    innate lymphoid cell regulation, 382–383
    long noncoding RNA regulation, 302–303
    signaling, 196–197, 205
  Interferon-α (IFN-α), cancer immunotherapy
    follicular lymphoma, 437
    Kaposi sarcoma, 437
    melanoma, 437–438
    toxicity, 438
  Interferon-γ (IFN-γ)
    antibodies, 457
    cancer immunotherapy role
      elimination phase, 229–231
      equilibrium, 231–232
      escape, 232–233
      overview, 227–229
    cancer studies, 176–177
    cellular sources, 220–221
    gene, 219
    immune cell activation
      B cell, 226–227
      dendritic cell, 226
      macrophage, 225–226
      T cells
        CD8^+ T cells, 227
        helper T cells, 227
        Tregs, 227
    interferon regulatory factor regulation, 211–212
    posttranslational modification, 220
    receptor
      activation, 224
      signaling pathway, 223, 225
      structure and function, 221–223
    types, 175
    virus infection treatment, 175–176
  Interferon regulatory factor (IRF)
    interferon-γ regulation, 211–212
    structure, 206
    type I interferon regulation
      cytosolic DNA recognition, 210–211
      cytosolic RNA recognition, 208–210
      Toll-like receptor signaling, 206–208
    type III interferon regulation, 212
    types, 206
  Interleukin-1 (IL-1)
    autoinflammatory disease studies
      cryopyrin-associated periodic syndromes, 262–263
      extrinsic inflammasomopathies, 265–267
      familial Mediterranean fever, 263–264
    interleukin-1 receptor antagonist deficiency, 265
    intrinsic inflammasomopathies, 261–265
    Majeed syndrome, 265
    mevalonate kinase deficiency, 266
    NLRC4-associated autoinflammatory diseases, 264
    NLRP12-associated autoinflammatory disorder, 265
    overview, 261
    pyogenic arthritis, pyoderma gangrenosum and acne syndrome, 265–266
    tumor necrosis factor receptor-associated periodic syndrome, 267
    cellular sources, 240–241
    expression regulation, 246
    family members, 239, 255–256
    immune regulation, 245–246
    immune stimulation by inflammasome-dependent cytokines, 260
    inflammasome-dependent processing, 256–260
    innate lymphoid cell regulation, 387
    nuclear function, 248
    overview, 239–240
    signaling regulation, 247–248
  Interleukin-2 (IL-2)
    autoimmune disease studies, 19–22
    cancer immunotherapy
      low-dose trials, 435–436
      melanoma, 434–435
      overview, 433–434
    CD8^+ T cell
      function, 16
      response to virus infection, 362–365, 370, 372
    functional overview, 2–3
    helper T cell
      differentiation role, 12–13, 15–16
      fate determination, 329
    history of study, 1–2
    innate lymphoid cell regulation, 381–382, 386
    natural killer cell function, 18
    receptors, 1–2, 5–6
    regulatory T-cell regulation, 346–350
    therapy, 22–25
    Treg function, 11–12, 14–15
  Interleukin-3 (IL-3)
    cancer studies, 46
    functional overview, 44
    nervous system function, 46–47
    receptor, 48–53
    sepsis and inflammation role, 45
    therapeutic targeting, 55
  Interleukin-4 (IL-4)
    B-cell function, 16–18
    functional overview, 3–4
    innate lymphoid cell regulation, 384–385
    macrophage function, 19
    natural killer cell function, 18–19
Interleukin-4 (IL-4) (Continued)
receptors, 6
T helper cell differentiation role, 12–14, 329
therapy, 25
Interleukin-5 (IL-5)
functional overview, 44
innate lymphoid cell regulation, 384, 389
nervous system function, 46–47
receptor, 48–53
therapeutic targeting, 55–56
Interleukin-6 (IL-6)
antibodies, 457
cloning of complex components, 66–67
expression regulation, 86–87
family of cytokines. See also specific cytokines
mutations and disease, 75–76
overview, 72
plasticity, 72–73
human herpes virus 8, 73
overview, 64–66, 83–85
receptor complex
gp130 subunit, 69
signaling, 68–69, 85–86
soluble receptor, 73–74
structure, 68
trans-signaling, 69–71, 74–75
therapeutic targeting
cytokine release syndrome, 93, 94
rationale, 88–89
sepsis, 93–94
tocilizumab therapy
Castleman disease, 89
giant cell arteritis, 92
juvenile idiopathic arthritis, 90
myocardial infarction, 94
neuromyelitis optica, 92
polymyalgia rheumatica, 92–93
rheumatoid arthritis, 89–90
systemic sclerosis, 90–91
Interleukin-7 (IL-7)
B-cell function, 16–18
functional overview, 4
innate lymphoid cell regulation, 381–382, 386
receptor, 6, 458
T-cell function
CD8+ T-cell function, 16, 365–368, 372–373
development role, 279–280
overview, 10–11
regulatory T-cell regulation, 351–353
Interleukin-9 (IL-9)
functional overview, 4
innate lymphoid cell regulation, 384–385
receptors, 6
T helper cell differentiation role, 12–14
Interleukin-10 (IL-10)
cancer
role, 165–166
therapeutic targeting, 166
cellular sources, 160
family members, 157–159
receptors, 158–159
structure, 158
systemic lupus erythematosus therapeutic targeting, 163
therapy
Crohn’s disease, 159, 161–162
mechanism of action in autoimmune disease, 159
rheumatoid arthritis, 162–163
strategies
antibody-conjugated IL-10, 164–165
bacteria expression for intestinal delivery, 163–164
ulcerative colitis, 159, 161
Interleukin-11 (IL-11)
mutations and disease, 75–76
trans-signaling, 75
Interleukin-12 (IL-12)
cancer immunotherapy, 438–439
cancer studies
antitumor immunity, 141
cross-regulation with interleukin-23, 148–150
receptor expression, 144–145
therapeutic targeting, 150
family members, 139
innate lymphoid cell regulation, 388
overview, 139–140
Interleukin-13 (IL-13), innate lymphoid cell regulation, 384
Interleukin-15 (IL-15)
cancer immunotherapy
clinical trials, 442–443
combination therapy, 443–444
immune response, 441–442
optimization, 443
overview, 440–441
preclinical studies, 441
toxicity, 441
CD8+ T-cell function, 16
response to virus infection, 368–370, 372–373
cutaneous T-cell lymphoma role, 448
dendritic cell function, 19
functional overview, 4–5
innate lymphoid cell regulation, 381–382
receptors, 6
regulatory T-cell regulation, 353–354
Interleukin-17 (IL-17)
cellular sources
IL-17A, 122–123
IL-17B, 124
IL-17C, 124
IL-17D, 124
IL-17E, 123–124
IL-17F, 122
infection studies
IL-17A, 129
IL-17E, 132
IL-17F, 128–129
inflammation studies
  IL-17B, 131
  IL-17C, 131–132
  IL-17D, 132
  IL-17E, 132
innate lymphoid cell regulation, 386–387
overview of family, 121–122
signaling
  IL-17A, 124–125
  IL-17B, 126
  IL-17C, 126
  IL-17D, 126
  IL-17E, 125–126
  IL-17F, 124–125
overview, 124
regulation, 127–128
skin disease studies, 129–131
Interleukin-19 (IL-19), cellular sources, 160
Interleukin-20 (IL-20)
cellular sources, 160
diabetic foot ulcer management, 174–175
psoriasis role and therapeutic targeting, 168–169
rheumatoid arthritis role and therapeutic targeting, 169–170
Interleukin-21 (IL-21)
autoimmune disease studies, 19–22
B-cell function, 16–18
cancer immunotherapy, 439
CD8+ T-cell function, 16
dendritic cell function, 19
functional overview, 5
natural killer cell function, 18–19
receptors, 7
T helper cell differentiation role, 15–16
Interleukin-22 (IL-22)
atopic dermatitis therapeutic targeting, 169
cellular sources, 160
inflammatory bowel disease therapy, 170–172
innate lymphoid cell regulation, 386–387
protective effects
  graft-versus-host disease, 173–174
  hepatitis, 173
  pancreatitis, 173
psoriasis role and therapeutic targeting, 168–169
Interleukin-23 (IL-23)
cancer studies
cellular sources, 142, 144
clinical relevance of expression, 142–143
cross-regulation with interleukin-12, 148–150
receptor expression, 144–147
therapeutic targeting, 150
tumor promotion, 141–142, 145, 147–148
tumor suppression, 142
overview, 139–140
Interleukin-24 (IL-24)
antitumor activity, 166–168
cellular sources, 160
Interleukin-26 (IL-26), cellular sources, 160
Interleukin-28 (IL-28), cellular sources, 160
Interleukin-29 (IL-29), cellular sources, 160
Interleukin-33 (IL-33)
cancer studies, 245
cellular sources, 240–241
expression regulation, 246
nuclear function, 248
overview, 239–240
regulatory T-cell regulation, 354–355
signaling regulation, 247–248
T helper cell responses
  Th1, 242–243
  Th2, 241–242
visceral adipose tissue homeostasis role, 243–244, 355
wound healing role, 244–245
Interleukin-37 (IL-37)
cellular sources, 240
nuclear function, 248
IPEX syndrome, 332
IFN. See Interferon regulatory factor
IRR. See Innate repair receptor

J
JAK
  β common family cytokine signaling, 51–52
  γ chain family cytokine signaling, 7, 9
overview of JAK-STAT pathway, 187–189, 314–315
therapeutic targeting, 25
therapeutic targeting in cancer, 444–447
JIA. See Juvenile idiopathic arthritis
Juvenile idiopathic arthritis (JIA), tocilizumab therapy, 90

K
Kaposi sarcoma, interferon-α therapy, 437
KIT, T-cell development role, 277, 279, 282–284

L
IncRNA. See Long noncoding RNA
Long noncoding RNA (IncRNA)
cell differentiation role with cytokines
dendritic cell, 297–298
erthrocytes, 296
hematopoiesis, 295–296
macrophage, 297
short-lived myeloid cells, 296–297
T cells
  CD8+ T cell, 298
  NeST, 298, 301
  Th1, 298, 301
  Th2, 301
  Th17, 301
  Treg, 302
cytokine production regulation by IncRNAs
  AS-IL-1α, 305
  IL-1β-RBT46, 305
  Inc-IL-7R, 305
Long noncoding RNA (lncRNA) (Continued)
lncRNA-Cox2, 304
lncRNA-EPS, 306
NEAT1, 305
NKILA, 305
PACER, 304–305
THRL, 304
cytokine regulation of RNAs
interferon, 302–303
tumor necrosis factor α, 302
diseases, 306–307
overview, 293–295
prospects for study, 307–308
therapeutic targeting, 307

M
Macrophage. See also Tumor-associated macrophage
interferon-γ in activation, 225–226
long noncoding RNA regulation of differentiation, 297
Majed syndrome, 265
Melanoma
interferon-α therapy, 437–438
interleukin-2 therapy, 434–435
Morbid, 296
MS. See Multiple sclerosis
Multiple sclerosis (MS)
β common family cytokines studies, 45
γ family cytokine studies, 21
MYB, T-cell development role, 282
Myocardial infarction, toclizumab therapy, 94

N
Natural killer cell, β chain family cytokine function, 18–19
NEAT1, 305
NeST, 298, 301, 303
Neuromyelitis optica (NMO), toclizumab therapy, 92
Neutrophil. See Tumor-associated neutrophil
NLRCA, 259–261, 264
NLRP3, 258–263
NLRP12-associated autoinflammatory disorder, 265
NMO. See Neuromyelitis optica
Notch, T-cell development role, 274, 276, 282
NRAV, 303
NRON, 303
NRPI, 386

P
PACER, 304–305
Pancreatitis, interleukin-22 protective effects, 173
PMR. See Polymyalgia rheumatica
Polymyalgia rheumatica (PMR), toclizumab therapy, 92–93
PRC2, 294
Psoriasis
interleukin-17 studies, 129–130, 132
interleukin-20 role and therapeutic targeting, 168–169
interleukin-23 therapeutic targeting, 151
PSTPIP1, 266
PTEN, 346
Pyogenic arthritis, pyoderma gangrenosum and acne
(PAPA) syndrome, 265–266

R
RA. See Rheumatoid arthritis
Regulatory T cell. See T cell
Renal cell carcinoma, interleukin-2 therapy, 434–435
Rheumatoid arthritis (RA)
γ chain family cytokine studies, 20–21
interleukin-10 studies, 162–163
interleukin-17 studies, 131
interleukin-20 role and therapeutic targeting, 169–170
toclizumab therapy, 89–90
RNA. See Long noncoding RNA
RORγt, Th cell studies
differentiation role, 331–332
expression by noncanonical Th cell subtypes, 332–333

S
Sepsis
β common family cytokine studies, 44–45
interleukin-6 therapeutic targeting, 94–95
SLE. See Systemic lupus erythematosus
SOCS
SOCS1
functional overview, 316
gene expression mediated, 9–10
helper T-cell regulation, 321
types, 315–316
SOCS3
cancer studies, 321
types, 315–316
SSc. See Systemic sclerosis
STAT
chromatin remodeling, 194–195
γ chain family cytokine signaling, 7–9
gene expression mediated, 9–10
intracellular localization, 194–197
interferon signaling, 196–197
mutations
gain-of-function mutations
infectious disease, 195–196
types, 195
negative regulation, 192
overview, 187–189
posttranslational modifications
glycosylation, 192
lysine and arginine, 191–192

phosphorylation
  serine, 189
  STAT1, 190
  STAT2, 190
  STAT3, 190
  STAT5A, 190
  STAT5B, 190
  STAT6, 190–191
  tyrosine, 192

SUMOylation, 192

Th cell fate determination, 328–330
therapeutic targeting in cancer, 444–447
unphosphorylated STATs
  gene expression regulation
    negative, 193–194
    positive, 192–193
  overview, 192
  U-STAT3 in mitochondria, 194

Systemic lupus erythematosus (SLE)
  γ chain family cytokine studies, 20
  interleukin-10 therapeutic targeting, 163

Systemic sclerosis (SSc), toclizumab therapy, 90–91

T
  TACI, 109
  TAM. See Tumor-associated macrophage
  TAN. See Tumor-associated neutrophil
  T cell
    CD8⁺ T-cell response to virus infection
      acute infection, 361–362
      chronic infection, 370–372
    interleukin-2, 362–365, 370, 372
    interleukin-7, 365–368, 372–373
    interleukin-15, 368–370, 372–373

CISH in differentiation, 317–318
development
  cell precursor flux regulation, 282–286, 280
  commitment in early development
    phase 1, 278–279
    phase 2, 280–281
    phase 3, 281–282
  early phases
    phase 1, 274
    phase 2, 274–275
    phase 3, 275–276
  GATA3 role, 277–278
  initiation by environmental signals and transcription factors, 276
  interleukin-7 in phase 1/phase 2 transition, 279–280
  overview, 273–274
  γ chain family cytokine function
    CD8⁺ T-cell development and differentiation, 16
development, 10–11
  T helper cell differentiation, 12–16
  Tregs, 11–12
  helper T cell
    differentiation
      cross-regulation, 332
      cytokine-mediated positive feedback, 330
      STATs in fate determination, 328–330
      transcription factors, 330–332
    effector T-cell relationship with Tfh cells, 334–335
    epigenetics and cell plasticity, 333–334
    functions by type, 328
    innate lymphoid cell relationship, 335–336
    types and cytokine production, 327–328
  interferon-γ in activation
    CD8⁺ T cells, 227
    helper T cells, 227
    Tregs, 227
  interleukin-33 and T helper cell responses
    Th1, 242–243
    Th2, 241–242
  long noncoding RNA regulation of differentiation
    CD8⁺ T cell, 298
    NeST, 298, 301
    Th1, 298, 301
    Th2, 301
    Th17, 301
    Treg, 302
  regulatory T-cell differentiation and homeostasis
    control by cytokines
      interleukin-2, 346–350
      interleukin-7, 351–353
      interleukin-15, 353–354
      interleukin-33, 354–355
      overview, 345–346
      therapeutic targeting, 355–356
      transforming growth factor β, 350–351
  SOCS regulation
    SOCS1
      antitumor immunity, 319–320
      differentiation, 314
      Tregs, 315
    SOCS3 and helper T cells, 321
  tumor necrosis factor in development and function, 104
    TCF1, 274, 277, 282
    TGF-β. See Transforming growth factor β
    THRIL, 304
  Thymic stromal lymphoprotein (TSLP), 329, 351, 353
  TLRs. See Toll-like receptors
  TNE. See Tumor necrosis factor
  Tocilizumab, therapy
    Castleman disease, 89
    giant cell arteritis, 92
    juvenile idiopathic arthritis, 90
    myocardial infarction, 94
    neuromyelitis optica, 99
    polymyalgia rheumatica, 92–93
    rheumatoid arthritis, 89–90
    systemic sclerosis, 90–91
  Toll-like receptors (TLRs), type I interferon regulation via
    interferon regulatory factor, 206–208
Index

TRAFA3, 347
TRAIL, 417, 421–422
Transforming growth factor β (TGF-β)
  regulatory T-cell regulation, 350–351
  Th cell fate determination, 329–330
TRAPS. See Tumor necrosis factor receptor-associated periodic syndrome
TSLP. See Thymic stromal lymphoprotein
Tumor necrosis factor (TNF)
  functions
    adaptive immunity, 104
    B-cell development and function, 105
    bone homeostasis, 103–104
    brain, 105
    cell death, 103
    ectodermal development, 104
    inflammation, 103
    lymphoid organs, 104
    overview of family, 99–103
    survival signaling, 103
    T-cell development and function, 104
    wound healing, 103
long noncoding RNA regulation of tumor necrosis factor α, 302
noncanonical coreceptors and ligands, 111–112
prospects for study, 114
regulation, 111, 113–114
signaling
  bidirectional signaling, 107
  induced juxtaposition, 105–107
  membrane anchoring of ligand and receptor, 107–108
  pathways, 111
  protein-binding motifs, 110–111
  re-anchoring, 107, 109–110
Tumor necrosis factor receptor-associated periodic syndrome (TRAPS), 267
Tumor-associated macrophage (TAM)
  anticancer therapeutic response, 421–423
  biomarker utilization in cancer, 419–421
  overview, 413
  tumor growth and progression role, 415–416
Tumor-associated neutrophil (TAN)
  anticancer therapeutic response, 421–423
  biomarker utilization in cancer, 419–421
  tumor growth and progression role, 416–419

U
UC. See Ulcerative colitis
Ulcerative colitis (UC)
  γ chain family cytokine studies, 20
  interleukin-10, 159, 161
  interleukin-22 therapy, 170–172
Ustekinumab, 151

V
Vascular endothelial growth factor (VEGF), 418, 459
VAT. See Visceral adipose tissue
VEGF. See Vascular endothelial growth factor
Visceral adipose tissue (VAT), interleukin-33 in homeostasis, 243–244, 355

X
Xist, 294
X-linked severe combined immunodeficiency (XSCID), IL2RG mutations, 2
XSCID. See X-linked severe combined immunodeficiency